|Videos|August 19, 2022
Second-Line Treatment Approaches for R/R DLBCL
Author(s)Ian Flinn, MD, PhD
An expert provides his perspective on the first- and second-line treatment approaches in the patient case and comments on the patient’s likely prognosis.
Advertisement
Episodes in this series
Advertisement
Related to this article
CELESTIMO trial shows mosunetuzumab plus lenalidomide boosts PFS in relapsed follicular lymphoma, supporting earlier-line outpatient, chemo-free care.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
IMS Day 1 Recap: Bispecific and CAR T Data Shape Myeloma Treatment
2
Rusfertide Receives NCCN Category 1 Designation in Polycythemia Vera
3
Global Experts Define Consensus Criteria for Cure in Multiple Myeloma
4
FDA Approves Lirafugratinib for FGFR2-Altered Cholangiocarcinoma
5